PMID- 23254795
OWN - NLM
STAT- MEDLINE
DCOM- 20130625
LR  - 20141120
IS  - 0018-1994 (Print)
IS  - 0018-1994 (Linking)
VI  - 58
IP  - 11
DP  - 2012 Nov
TI  - [Adverse events associated with temsirolimus for patients with metastatic renal 
      cell carcinoma].
PG  - 651-4
AB  - Temsirolimus is an inhibitor of mammalian target of rapamycin, with proven 
      efficacy against advanced renal cell carcinoma (RCC), particularly poor risk 
      and/or non-clear cell RCC, in a randomized first-line phase III trial. In this 
      trial, adverse events (AEs)>/=grade 3 occurred in 47.6% of patients treated with 
      temsirolimus alone (n＝208), and the common AEs included asthenia, anemia and 
      hyperglycemia. During the observation period of this trial, drug-related 
      pneumonitis was detected ; 4 patients developed temsirolimus-related pneumonitis, 
      including 2 with >/=grade 3. To date, there have not been any reports analyzing 
      data from a large number of Japanese RCC patients treated with temsirolimus. 
      However, judging from our experience, the severity as well as the frequency of 
      AEs associated with temsirolimus in Japanese patients seem to be similar to those 
      in the Western population. In this study, we summarize our clinical experience 
      with the use of temsirolimus focusing on its AEs and try to clarify the 
      characteristics of temsirolimus-related AEs in Japanese patients, and then 
      present our data relevant to this point from our clinical studies in order to 
      discuss the significance of the management of AEs encountered during treatment 
      with temsirolimus.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - The Division of Urology, Kobe University Graduate School of Medicine.
FAU - Fujisawa, Masato
AU  - Fujisawa M
LA  - jpn
PT  - Clinical Trial, Phase III
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Japan
TA  - Hinyokika Kiyo
JT  - Hinyokika kiyo. Acta urologica Japonica
JID - 0421145
RN  - 0 (Antineoplastic Agents)
RN  - 624KN6GM2T (temsirolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*adverse effects
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Molecular Targeted Therapy/adverse effects
MH  - Neoplasm Metastasis
MH  - Pneumonia/chemically induced
MH  - Sirolimus/adverse effects/*analogs & derivatives
EDAT- 2012/12/21 06:00
MHDA- 2013/06/26 06:00
CRDT- 2012/12/21 06:00
PHST- 2012/12/21 06:00 [entrez]
PHST- 2012/12/21 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
PST - ppublish
SO  - Hinyokika Kiyo. 2012 Nov;58(11):651-4.